A prospective interventional study in chronic prostatitis with emphasis to clinical features.

PURPOSE Chronic bacterial prostatitis displays a variety of symptoms (mainly local pain exhibiting vari­ability in origin and intensity). These symptoms often persist despite bacterial eradication. The purpose of this article is to exam the role of phytotherapeutic agents as complementary treatment in patients with bacterial prostatitis. MATERIALS AND METHODS The material consisted of individuals with reported pelvic discomfort and genital pain with or without lower urinary tract symptoms (LUTS) and sexual dysfunction visiting our department from March 2009 to March 2011. Patients underwent Stamey-Meares test (several cases underwent the two glass test). Depending on history and specific symptoms urethral smear and semen cultures were additionally obtained from several patients. All patients were randomized into two groups. Subjects in the first group (72 patients) received appropriate antibiotic (according to the sensitivity test) for 15 days, while subjects in the second group (72 patients) received phytotherapeutic agents for 30 days, additionally the conventional 15 days antibiotic treatment. The response was tested using laboratory and clinical criteria. RESULTS We found no statistically significant differences between the two groups regarding bacterial and symptom persistence rate, however, symptoms burden was lower in patients receiving combinational treatment. CONCLUSION Phytotherapeutic agents may improve pain and prostatitis related difficulty in urination. Further randomized, placebo-controlled studies are needed to substantiate safer conclusions.

[1]  T. Nguyen,et al.  Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP‐1/CCL2 and VCAM‐1, in vitro , 2012, BJU international.

[2]  Xiaohai Wang,et al.  Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia (BPH) , 2012, The Journal of Biological Chemistry.

[3]  A. Vinarov,et al.  [Treatment of chronic prostatitis in prophylaxis of prostatic adenoma]. , 2012, Urologiia.

[4]  G. Norstedt,et al.  Androgen‐independent Effects of Serenoa repens Extract (Prostasan®) on Prostatic Epithelial Cell Proliferation and Inflammation , 2012, Phytotherapy research : PTR.

[5]  Kul'chavenia Ev,et al.  Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections , 2010 .

[6]  C. Pavone,et al.  [Associating Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower urinary tract symptoms. Prospective study on 320 patients]. , 2010, Urologia.

[7]  D. Kholtobin,et al.  [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections]. , 2010, Urologiia.

[8]  F. Claessens,et al.  The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth , 2009, Journal of cellular and molecular medicine.

[9]  T. Cai,et al.  Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. , 2009, International journal of antimicrobial agents.

[10]  G. Perletti,et al.  Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. , 2007, International journal of antimicrobial agents.

[11]  J. Nickel,et al.  Chronic bacterial prostatitis: an evolving clinical enigma. , 2005, Urology.

[12]  M. Elhilali,et al.  Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH , 2005, BJU international.

[13]  N. Kyprianou,et al.  Effect of permixon on human prostate cell growth: Lack of apoptotic action , 2004, The Prostate.

[14]  C. Roberts,et al.  Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. , 2004, Endocrinology.

[15]  D. Engeler,et al.  EAU Guidelines on chronic pelvic pain , 2016 .

[16]  J. Krieger,et al.  Chronic prostatitis: symptom survey with follow-up clinical evaluation. , 2003, Urology.

[17]  U. Jonas,et al.  [Phytotherapy of benign prostatic hyperplasia. Current evidence-based evaluation]. , 2002, Der Urologe. Ausg. A.

[18]  V. Tyler,et al.  Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. , 2001, Urology.

[19]  R. Levin,et al.  A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens , 2000, Urological Research.

[20]  M. Barry,et al.  How common is prostatitis? A national survey of physician visits. , 1998, The Journal of urology.

[21]  F. Bracher.  Phytotherapie der benignen Prostatahyperplasie , 1997, Der Urologe A.

[22]  A. Granata,et al.  [Urological and sexual evaluation of treatment of benign prostatic disease using Pygeum africanum at high doses]. , 1991, Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences.